Evidence map›Paper›PMID 31982992›Full record

ArticleEsophagus : official journal of the Japan Esophageal Society2020

Clinical utility of salivary pepsin measurement in patients with proton pump inhibitor-refractory gastroesophageal reflux disease symptoms: a prospective comparative study.

Tomoaki Matsumura, Makoto Arai, Takeshi Suzuki, Toshitaka Hoppo, Yosuke Seki, Shingo Kasamatsu, Hideaki Ishigami, Kentaro Ishikawa, Kenichiro Okimoto, Naoki Akizue and 5 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Esophagus : official journal of the Japan Esophageal Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Diagnostic performance of salivary pepsin for gastroesophageal reflux disease.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Tomoaki MatsumuraDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, 260-8670, Japan. matsumura@chiba-u.jp.ORCID 0000-0001-5314-9325
Makoto AraiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, 260-8670, Japan.
Takeshi SuzukiDepartment of Otorhinolaryngology, Head and Neck Surgery, Chiba University, Chiba, Japan.
Toshitaka HoppoEsophageal and Lung Institute, Allegheny Health Network, 4815 Liberty Avenue, Mellon Pavilion, Suite 158, Pittsburgh, PA, 15224, USA.
Yosuke SekiWeight Loss and Metabolic Surgery Center, Yotsuya Medical Cube, Tokyo, Japan.
Shingo KasamatsuDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, 260-8670, Japan.
Hideaki IshigamiDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, 260-8670, Japan.
Kentaro IshikawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, 260-8670, Japan.
Kenichiro OkimotoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, 260-8670, Japan.
Naoki AkizueDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, 260-8670, Japan.
Daisuke MaruokaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, 260-8670, Japan.
Tomoo NakagawaDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, 260-8670, Japan.
Takeo OdakaOdaka Medical and Gastrointestinal Clinic, Chiba, Japan.
Yoshitaka OkamotoDepartment of Otorhinolaryngology, Head and Neck Surgery, Chiba University, Chiba, Japan.
Naoya KatoDepartment of Gastroenterology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba, 260-8670, Japan.
Chiba University · JPAllegheny Health Network · USYotsuya Medical Cube · JP

Funding

Japan Society for the Promotion of Science 18K09367
6 · The paper itself

Abstract

backgroundSalivary pepsin measurement has been reported to be useful for diagnosing gastroesophageal reflux disease (GERD). This study aimed to clarify the usefulness of salivary pepsin measurement in patients with proton pump inhibitor (PPI)-refractory GERD symptoms without erosive esophagitis.

methodsOne hundred and two patients were included. Over seven days after terminating PPI treatment, all patients underwent a 24-h pH-impedance test and salivary pepsin measurement. In patients whose main symptoms included laryngopharyngeal symptoms, a hypopharyngeal multichannel intraluminal impedance (HMII) test was performed, whereas in other patients, a conventional combined multichannel intraluminal impedance-pH (MII-pH) test was performed. In the HMII tests, patients were divided into abnormal proximal exposure (APE) and non-APE groups. Salivary pepsin concentrations were compared according to acid exposure time (AET) values and were also compared between the APE and non-APE groups.

resultsThe median salivary pepsin concentration in patients with AET > 6% was significantly higher than that in patients with AET ≤ 6% (345.0 [170.0-469.3] ng/mL vs. 120.0 [97.0-290.1] ng/mL, p < 0.01). The sensitivity, specificity, positive predictive value, and negative predictive value of a positive test (> 109 ng/mL) to diagnose patients with AET > 6% were 75.0%, 51.3%, 32.1%, and 86.9%, respectively. There was no significant difference between concentrations in the APE group and concentrations in the non-APE group.

conclusionsIn patients with PPI-refractory nonerosive reflux disease, salivary pepsin measurement may help diagnose patients who have conclusive evidence of reflux, whereas it is not adequate for identifying patients with APE.

Indexed as

AdultAgedDrug ResistanceElectric ImpedanceEsophageal pH MonitoringFemaleGastroesophageal RefluxHumansHypopharynxLaryngopharyngeal RefluxMaleMiddle AgedPepsin APredictive Value of TestsProspective StudiesProton Pump InhibitorsPepsin AProton Pump InhibitorsGERDLPRNERDPpi-refractory GERDSalivary pepsin

Identifiers

PMID31982992
OpenAlexW3001890836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.